VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2021 | JAVELIN Bladder 100 trial updates from ASCO 2021

Petros Grivas, MD, PhD, University of Washington School of Medicine & Fred Hutchinson Cancer Research Center, Seattle, WA, speaks of the change in standard of care accomplished by the JAVELIN Bladder 100 trial (NCT02603432). The study looks at the effect of the PD-L1 immune checkpoint inhibitor avelumab compared with best supportive care alone. Updates to the data set indicated several findings: there is no clinical or molecular factor which can influence the selection of patients that receive avelumab maintenance treatment. Dr. Grivas believes all patients should receive avelumab therapy regardless of any clinical or molecular biomarkers, as long as there is no contra-indication to immunotherapy. Secondly, avelumab therapy causes an increase in the time from randomization to the next line of therapy, signifying the overall survival benefit of this treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter